Harnessing Pharmacogenomics in Palliative Care: A New Frontier for Personalized Symptom Management
As palliative care continues to evolve with an emphasis on quality of life, comfort, and symptom control, the incorporation of precision medicine tools like pharmacogenomics (PGx) offers promising benefits. Pharmacogenomics, the study of how a patient’s genetic makeup influences their response to medications, can serve as a powerful ally for healthcare professionals managing complex, multi-symptom patients at the end of life.
Understanding Pharmacogenomics in the Palliative Context
Palliative care patients often face multiple distressing symptoms, including pain, nausea, anxiety, depression, and dyspnea, many of which require pharmacologic intervention. Compounded by altered organ function and polypharmacy, medication management in this population can be challenging. Pharmacogenomics helps tailor medication regimens by predicting how a patient may metabolize and respond to specific drugs, minimizing trial-and-error prescribing and avoiding ineffective or harmful therapies.
Key Genetic Markers and Drug Implications in Palliative Care
Several gene-drug interactions are especially relevant to palliative care practice:
CYP2D6 Gene
Affects metabolism of Codeine, Tramadol, Oxycodone, SSRIs
Clinical Relevance: Poor or ultra-rapid metabolizers may experience inadequate analgesia or excessive side effects.
CYP2C19 Gene
Affects metabolism of Citalopram, Diazepam
Clinical Relevance: May require dose adjustments based on metabolic rate.
COMT Gene
Affects opioid responsiveness, pain perception
Clinical Relevance: May help predict opioid dose requirements.
UGT1A1 Gene
Morphine, Irinotecan (is an anti-cancer medication used to treat colon cancer and small cell lung cancer)
Results in poor glucuronidation can lead to drug accumulation and toxicity.
Opioid Receptor mu-1 (OPRM1)
Affects opioid receptor binding.
May influence individual variability in opioid effectiveness.
Clinical Application: A Case Study
Mr. L is a 72-year-old man with metastatic pancreatic cancer who is receiving home-based palliative care. His main symptoms include poorly controlled abdominal pain, nausea, and anxiety. His current medication regimen consists of codeine/acetaminophen, lorazepam, metoclopramide, and sertraline. Despite escalating doses, his pain remains poorly controlled. He is also sedated and nauseated, raising concerns about possible medication-related adverse effects.
Pharmacogenomic testing revealed that Mr. L is a CYP2D6 poor metabolizer, meaning he cannot effectively convert codeine to morphine, rendering his current opioid ineffective. He is also a CYP2C19 ultra-rapid metabolizer, suggesting that sertraline is likely subtherapeutic. Additionally, the CYP2D6 variant may be impairing clearance of metoclopramide, potentially contributing to his sedation and nausea.
In response to these findings, the clinical team made several targeted interventions. Codeine was switched to hydromorphone, which does not rely on CYP2D6 metabolism. Metoclopramide was discontinued, and ondansetron was initiated if compatible. Sertraline was replaced with escitalopram to better match his metabolizer status. Lorazepam dosing was monitored and adjusted as needed. These changes led to improved control of Mr. L’s pain and nausea, enhanced alertness and comfort, and increased satisfaction among his caregivers.
What does Pharmacogenomic Workflow Look Like?
A practical pharmacogenomic workflow for palliative care begins with identifying appropriate candidates—patients with inadequate symptom control, atypical drug responses, or those on multiple high-risk medications. Pharmacogenomic testing should ideally include panels covering CYP2D6, CYP2C19, UGT1A1, COMT, OPRM1, and others. Results must be interpreted thoughtfully, often with input from genetic counselors or pharmacists. Medications are then tailored accordingly, especially opioids, antidepressants, antiemetics, and anxiolytics. It is essential to document all genetic findings and related clinical decisions while regularly reassessing treatment efficacy and side effects.
However, certain considerations and limitations remain. The timing of pharmacogenomic testing may not align with the urgent needs of acute palliative care. Additionally, cost and access issues persist, as testing is not always covered by insurance or widely available. Interpretation of results requires clinician education and experience, and ethical concerns may arise when applying such testing in vulnerable or terminally ill populations.
Interested in learning more or integrating pharmacogenomic testing in your practice?
Looking ahead, as pharmacogenomic testing becomes faster and more affordable, its role in palliative care is likely to expand. Preemptive testing for patients with advanced illnesses, particularly those transitioning into palliative pathways, could become standard practice. Integration with electronic health records and decision-support tools may enhance its utility. Ultimately, for healthcare providers in palliative care, pharmacogenomics represents more than just genetics—it offers a pathway to precision, personalization, and deeply compassionate, patient-centered care at life’s most vulnerable stage.
Reach out to local labs offering comprehensive panels or collaborate with clinical pharmacists trained in pharmacogenomics. The future of palliative care is personal—and it's already here.
References:
- Bell, Caroline and Patel, Martyn. Pharmacogenomics and symptom management in palliative and supportive care: A scoping review. January 13, 2025. Volume 15(2): 158-167.
- Johnson, Julie A. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends in Genetics, Volume 19, Issue 11, 660 - 666.
- “Overview of pharmacogenomics". Up-to-Date. May 16, 2014. Retrieved 2025-04-05.
